TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02444065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Description: The CBT intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol developed by the investigators. It uses standard CBT for eating disorders interventions, including orientation to the CBT model, psychoeducation, commitment and goal setting, behavioral strategies for normalizing eating and reducing bulimic symptoms, planning, and homework. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing (MI)
Description: The MI intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol (Carter \& Bewell-Weiss, 2012). It uses standard MI for eating disorders interventions, including decisional balance, exploring values, readiness and confidence rules, and MI communication strategies. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
Study: NCT02858895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDNA55
Description: MDNA55 is an engineered circularly permuted interleukin-4 (cpIL-4) genetically fused to the catalytic domain of the pseudomonas exotoxin A (PE).
Study: NCT03831932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenastat Hydrochloride
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study: NCT00865878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic Acid
Description: 20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) ALA-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle ingredients only (VEH) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) VEH-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
Study: NCT00957684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eslicarbazepine acetate
Description: once-daily oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eslicarbazepine acetate
Description: once-daily oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eslicarbazepine acetate
Description: once-daily oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eslicarbazepine acetate
Description: once-daily oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily placebo comparator
Study: NCT02802124

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon-ion radiotherapy for tumor away from GI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon-ion radiotherapy for tumor adjacent to GI
Study: NCT01199835

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Calcium intake from dairy products
Description: High dietary intake of calcium from dairy products (\~1200 mg/d)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Calcium intake from dairy products
Description: High dietary intake of calcium from dairy products (\~1200 mg/d)
Study: NCT02506556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYl719
Description: Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.~Dose reductions (two levels) are allowed. Each cycle is 28 days
Study: NCT01097590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TLA Gut™ column
Description: Five consecutive treatment sessions. The therapy will be administrated every second day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Five consecutive treatment sessions. The placebo therapy will be administrated every second day.
Study: NCT03163758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real Repetitive Transcranial Magnetic Stimulation
Description: The rTMS treatments were performed using a Medtronic MagPro type magnetic stimulation device (Medtronic, Minneapolis, MN, USA) and a figure-of-eight coil (MC-B70, Medtronic). Coils were placed tangent to the scalp. The stimulation protocol involved 50 trains of 20 pulses applied over the ipsilesional M1 at a frequency of 5 HZ, with the stimulus intensity set at 120% of the resting motor threshold of the unaffected extremity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Repetitive Transcranial Magnetic Stimulation
Description: The sham rTMS was performed on the same site as the rTMS treatment group but without any true stimulations. Coils were placed perpendicular to the scalp.
Study: NCT04278287

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 59.92Gy and 2.14Gy in 28 fractions to PGTV and 50.4Gy and 1.8Gy in 28 fractions 5 days every week in 5.5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 100mg/d weekly,repeatedly on the first day,by intravenous infusion in 5-6 weeks.
Study: NCT03640390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: This group will receive Dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: This group will receive Magnesium sulphate infusion at a rate of 15 mg/Kg/hour
Study: NCT04278287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 weekly,by intravenous infusion in 5-6 weeks.
Study: NCT02477696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants will receive oral acalabrutinib as stated in arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Participants will receive oral ibrutinib as stated in arm description.
Study: NCT03640390

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: This group will receive normal saline infusion
Study: NCT00763425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold polypectomy
Description: The removal of small colorectal polyps up to 8 mm is performed using cold snare polypectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional polypectomy
Description: The removal of small colorectal polyps up to 8 mm is performed using conventional polypectomy.
Study: NCT03683225

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CTC-413
Description: pramipexole ER, given with aprepitant
Study: NCT00212342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethisterone,Ethinylestradiol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Study: NCT04159857

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fetal head extraction technique during the cesarean section
Description: see above for the description about one-hand and two-hand fetal head extraction technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal head extraction technique during the cesarean section
Description: see above for the description about one-hand and two-hand fetal head extraction technique
Study: NCT03117660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: vitamin A daily X3-4 weeks
Study: NCT02101853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo cranial radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo cranial radiation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01217164

Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: no intervention
Description: received enteral diet with 4.5 g / kg / day of protein and 160cal/Kg/dia
Study: NCT02868489

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LactoWise®
Description: blend of bacillus coagulans and galactomannans

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be selected is calcium carbonate (since participant routine standard of care already includes intake of calcium citrate)
Study: NCT04510623

Intervention type: OTHER
Intervention: ARBs and/or ACE inhibitors
Description: This is an observational study only.

Intervention type: OTHER
Intervention: ARBs and/or ACE inhibitors
Description: This is an observational study only.

Intervention type: OTHER
Intervention: ARBs and/or ACE inhibitors
Description: This is an observational study only.

Intervention type: OTHER
Intervention: Usual Care
Description: This is an observational study only.
Study: NCT01451528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Umbilical Cord Blood
Description: Allogeneic Umbilical Cord Blood Transplantation via Intravenous or Intraarterial route
Study: NCT02236871

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 servings
Description: Participants will receive motivational counseling to help the improve milk and milk product intakes to 2 servings per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 servings
Description: Participants will receive motivational counseling to help them increase their milk and milk product intake to 4 servings per day.
Study: NCT01126814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib (Gleevec)
Study: NCT04074369

Intervention type: DIAGNOSTIC_TEST
Intervention: CRISPR-based Test
Description: CRISPR-based Test performed on sputum or BALF in TB suspects.
Study: NCT03738670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous RFA
Description: Single session percutaneous extra-spinal bone metastasis destruction to achieve pain relief
Study: NCT03373084

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion

Intervention type: OTHER
Intervention: ultrasound
Description: Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion

Intervention type: OTHER
Intervention: Self-questionnaire
Description: Self-questionnaire will be completed by patient. In this questionnaire patients will describe the circumstances of the injury and their personal characteristics and level of sporting practice.
Study: NCT02405611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral
Description: The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: primary eduction
Description: The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
Study: NCT02792413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Patients will receive a subcutaneous injection of Denosumab every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (placebo)
Description: Patients will receive a subcutaneous injection of NaCl every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
Study: NCT02608216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FLT
Description: \[18F\]FLT PET/CT scan, imaging tracer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: \[18F\]FLT PET/CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: therapeutic
Study: NCT00566020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BW430C (lamotrigine)
Description: lamotrigine 50mg/day-400mg/day
Study: NCT02282813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101 Capsules
Description: At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101 Capsules
Description: At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101 Capsules
Description: At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101 Capsules
Description: At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxercalciferol
Description: At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily
Study: NCT04940793

Intervention type: DEVICE
Intervention: POD FT
Description: Cataract surgery
Study: NCT01544387

Intervention type: OTHER
Group type: OTHER
Intervention: Bed Rest
Description: * Subjects are admitted to their labor and delivery room and will spend the majority of their day in their hospital bed, usually in a reclined or sleeping position~* Subjects will be instructed to refrain from walking or engaging in any extraneous activity, including lifting or spending any extended period of time out of bed~* Subjects may have limited bathroom privileges

Intervention type: OTHER
Group type: OTHER
Intervention: Activity
Description: * Subjects are admitted to their labor and delivery room and will spend the majority of their time in their hospital bed~* Subjects will be given the opportunity of 3 periods of walking around their room and/or the hall on labor and delivery each day, each period consisting of approximately 20 minutes - this is the minimum activity level required for the study. Subjects are permitted more activity as desired.
Study: NCT01827267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Study: NCT03644394

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of IMES sensors
Description: Surgical implantation of IMES sensors during routine surgery to improve prosthetic control
Study: NCT04604613

Intervention type: PROCEDURE
Intervention: Bilateral Salpingectomy with Oophorectomy
Description: Undergo standard of care bilateral salpingo-oophorectomy

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: PROCEDURE
Intervention: Hysterectomy
Description: Undergo standard of care hysterectomy
Study: NCT04165278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperthermic baths
Description: Taking hyperthermic baths
Study: NCT04604613

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Intervention: Lymph Node Mapping
Description: Undergo sentinel lymph node mapping

Intervention type: PROCEDURE
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo sentinel lymph node biopsy
Study: NCT03792100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmofKabiven emulsion for infusion
Description: Total Parenteral Nutrition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hospital compounded All in one emulsion
Description: Total Parenteral Nutrition
Study: NCT01463189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: painACTION: Arthritis
Description: Participants will be asked to complete eight 20-minute sessions on the site over a four-week intervention period (two site visits per week), and complete five 20-minute booster sessions (one site visit per month) during the follow up period. Each session will have a minimum set of requirements. Specific details about the requirements for each session will be provided in the session logs.
Study: NCT03133442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnomat V4
Description: Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
Study: NCT04775784

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of SARS-CoV2 presence in CNS
Description: Brain tissue sampling
Study: NCT01380028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral corticosteroids
Description: Active treatment is prednisone establishment within 72 hours after the end of surgery at the dose of 1 mg / kg (rounded to the nearest 10 mg) once daily orally for one week . The daily dose then decreases in increments of 10 mg weekly, by the second week. Once the level of 10 mg / day reached the daily dose by one level lower than 5 mg weekly. Treatment is stopped after this week to 5 mg / day (average 2 months of treatment)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05585463

Intervention type: PROCEDURE
Intervention: acupuncture
Description: Acupuncture with needles and intracutaneous needles in the ear or body. The insertion is done with gloves, a guide to puncture the needle, and exhaustive skin disinfection.
Study: NCT02549742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Description: Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator
Description: Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Administered intravenously or injected into the tumour before electroporation.
Study: NCT01398579

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroscopy
Description: 20 patients will be randomized into two groups. All of them will be examined using four different endoscopy imaging technologies by one trained specialist. 10 patients will be in group A and another 10 patients will be in group B.~Group A: WLE followed by AFI followed by NBI followed by pCLE. Group B: WLE followed by NBI followed by AFI followed by pCLE.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroscopy
Description: 20 patients will be randomized into two groups. All of them will be examined using four different endoscopy imaging technologies by one trained specialist. 10 patients will be in group A and another 10 patients will be in group B.~Group A: WLE followed by AFI followed by NBI followed by pCLE. Group B: WLE followed by NBI followed by AFI followed by pCLE.